References
- Markham A, Lamb HM. Infliximab: a review of its use in the man-agement of rheumatoid arthritis. Drugs 2000;59:1341–59.
- Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098–104.
- Medical Section of the American Lung Association. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997;156(2 pt 2):S1–25.
- Benson CA, Ellner JJ. Mycobacterium avium complex infection and AIDS: advances in theory and practice. Chin Infect Dis 1993;17:7–20.
- Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. Arthritis Rheum 2003;48:2122–7.
- Schaible TF, Keenan GF, Hendricks DF, Tynan K, Curry S, et al. The Impact of a tuberculosis (Tb) awareness education program on Tb testing by physicians in a RA population. Arthritis Rheum 2002;46 suppl 9:S246.
- Opravil M. Epidemiological and clinical aspects of mycobacterial infections. Infection 1997;25(456–9.